S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Forecast, Price & News

$6.20
+0.03 (+0.49%)
(As of 09/20/2023 ET)
Compare
Today's Range
$6.08
▼
$6.39
50-Day Range
$6.17
▼
$7.69
52-Week Range
$5.53
▼
$11.48
Volume
70,388 shs
Average Volume
128,432 shs
Market Capitalization
$393.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Edgewise Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
335.5% Upside
$27.00 Price Target
Short Interest
Bearish
13.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.01mentions of Edgewise Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.58) to ($1.96) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

816th out of 962 stocks

Pharmaceutical Preparations Industry

387th out of 450 stocks

See Top Rated MarketRank™ Stocks Here

EWTX stock logo

About Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

EWTX Price History

EWTX Stock News Headlines

September 21, 2023 | americanbankingnews.com
Brokers Issue Forecasts for Edgewise Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:EWTX)
September 14, 2023 | finance.yahoo.com
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
September 21, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
September 5, 2023 | finance.yahoo.com
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet
August 16, 2023 | markets.businessinsider.com
Where Edgewise Therapeutics Stands With Analysts
August 16, 2023 | finance.yahoo.com
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 224.25%: Here's is How to Trade
August 14, 2023 | markets.businessinsider.com
Edgewise Therapeutics (EWTX) Receives a Buy from Truist Financial
July 17, 2023 | finance.yahoo.com
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
September 21, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
July 6, 2023 | msn.com
Edgewise Therapeutics (EWTX) Price Target Increased by 19.66% to 28.56
June 29, 2023 | msn.com
RBC Capital Reiterates Edgewise Therapeutics (EWTX) Outperform Recommendation
June 27, 2023 | msn.com
Truist Securities Reiterates Edgewise Therapeutics (EWTX) Buy Recommendation
June 27, 2023 | markets.businessinsider.com
Truist Financial Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)
June 27, 2023 | markets.businessinsider.com
Edgewise Therapeutics (EWTX) Gets a Sell from Goldman Sachs
June 27, 2023 | msn.com
CIRCOR International, Enovix, Edgewise Therapeutics And Other Big Stocks Moving Higher On Tuesday
June 26, 2023 | finance.yahoo.com
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
June 6, 2023 | finance.yahoo.com
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
May 16, 2023 | msn.com
JP Morgan Maintains Edgewise Therapeutics (EWTX) Overweight Recommendation
May 12, 2023 | msn.com
Wedbush Reiterates Edgewise Therapeutics (EWTX) Outperform Recommendation
May 12, 2023 | markets.businessinsider.com
RBC Capital Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)
May 11, 2023 | msn.com
Edgewise Therapeutics: Q1 Earnings Insights
May 1, 2023 | markets.businessinsider.com
Flexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise Therapeutics
May 1, 2023 | msn.com
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
May 1, 2023 | msn.com
Truist Securities Initiates Coverage of Edgewise Therapeutics (EWTX) with Buy Recommendation
March 30, 2023 | finance.yahoo.com
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
March 21, 2023 | finance.yahoo.com
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
March 14, 2023 | finance.yahoo.com
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
See More Headlines
Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EWTX Company Calendar

Last Earnings
8/10/2023
Today
9/21/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EWTX
CUSIP
N/A
CIK
1710072
Web
www.edgewisetx.com
Phone
720-262-7002
Fax
N/A
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+335.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-67,640,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-24.09%
Return on Assets
-22.86%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.01
Quick Ratio
22.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.48 per share
Price / Book
1.13

Miscellaneous

Outstanding Shares
63,460,000
Free Float
43,184,000
Market Cap
$393.45 million
Optionable
Not Optionable
Beta
-0.26
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Peter A. Thompson FACP (Age 63)
    M.D., Co-Founder & Independent Chairman
    Comp: $73k
  • Dr. Kevin Koch Ph.D. (Age 63)
    Pres, CEO & Director
    Comp: $913.1k
  • Dr. Badreddin Edris Ph.D. (Age 36)
    Co-Founder & Independent Director
    Comp: $40k
  • Dr. Alan J. Russell Ph.D. (Age 53)
    Co-Founder, Chief Scientific Officer & Director
    Comp: $657.52k
  • Dr. Joanne M. Donovan M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $695.48k
  • Mr. R. Michael Carruthers (Age 65)
    Chief Financial Officer
  • Mr. John R. Moore (Age 59)
    Gen. Counsel
  • Dr. Behrad Derakhshan Ph.D. (Age 43)
    Chief Bus. Officer
  • Dr. Marc Semigran M.D. (Age 66)
    Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













EWTX Stock - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EWTX shares.
View EWTX analyst ratings or view top-rated stocks.

What is Edgewise Therapeutics' stock price forecast for 2023?

4 analysts have issued 12-month price objectives for Edgewise Therapeutics' shares. Their EWTX share price forecasts range from $25.00 to $29.00. On average, they expect the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 335.5% from the stock's current price.
View analysts price targets for EWTX or view top-rated stocks among Wall Street analysts.

How have EWTX shares performed in 2023?

Edgewise Therapeutics' stock was trading at $8.94 at the start of the year. Since then, EWTX shares have decreased by 30.6% and is now trading at $6.20.
View the best growth stocks for 2023 here.

When is Edgewise Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our EWTX earnings forecast.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.07.

What ETF holds Edgewise Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 4,907 shares of EWTX stock, representing 0.70% of its portfolio.

When did Edgewise Therapeutics IPO?

(EWTX) raised $150 million in an IPO on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO.

What is Edgewise Therapeutics' stock symbol?

Edgewise Therapeutics trades on the NASDAQ under the ticker symbol "EWTX."

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.95%), Deep Track Capital LP (4.33%), Goldman Sachs Group Inc. (2.76%), Geode Capital Management LLC (1.35%), State Street Corp (1.18%) and Granahan Investment Management LLC (1.02%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers.
View institutional ownership trends.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edgewise Therapeutics' stock price today?

One share of EWTX stock can currently be purchased for approximately $6.20.

How much money does Edgewise Therapeutics make?

Edgewise Therapeutics (NASDAQ:EWTX) has a market capitalization of $393.45 million. The company earns $-67,640,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How can I contact Edgewise Therapeutics?

Edgewise Therapeutics' mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The official website for the company is www.edgewisetx.com. The company can be reached via phone at 720-262-7002 or via email at ir@edgewisetx.com.

This page (NASDAQ:EWTX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -